Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita
Diseases of the Integumentary System
What is the purpose of this trial?
This study evaluates the safety and efficacy of PTX-022, topical rapamycin, in the treatment of adults with moderate to severe Pachyonychia Congenita.
This study includes four-parts, and if a participant completes all parts, the participant will have received at least 3-months of PTX-022 treatment.
- Ages18 years and older
- Trial withPalvella Therapeutics, Inc.
- Start Date06/16/2019
- End Date12/30/2019
- Last Updated08/06/2019
- Study HIC#2000024725